GlassScriptPhysician profile
Erin Keech
NPI 1700906088
$1,720.56
in general payments reported to CMS, 2019-2025
33 companies · $218 in 2025
The $218 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $301 · 2022: $204 · 2023: $525 · 2024: $471 · 2025: $218.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,215.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,214.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $380.77 | 2021-2024 | Zeposia |
| Janssen Biotech, INC. | $118.72 | 2021-2023 | Simponi, Stelara, Remicade |
| Boston Scientific Corporation | $103.91 | 2023-2025 | Axonics, Exalt Model D, Apollo Esg System |
| Digestive Care, INC. | $87.59 | 2022-2024 | Pertzye |
| Qol Medical, LLC | $80.30 | 2023-2025 | Sucraid, Sucraid |
| Genzyme Corporation | $75.25 | 2023-2025 | |
| Medtronic, INC. | $69.62 | 2021-2022 | |
| Daiichi Sankyo INC. | $61.72 | 2021-2022 | |
| Ferring Pharmaceuticals INC. | $58.62 | 2023-2024 | Rebyota |
| Organon LLC | $51.50 | 2021-2023 | Renflexis, Hadlima |
| Mauna Kea Technologies, INC. | $49.67 | 2021-2024 | |
| Apollo Endosurgery US INC | $44.70 | 2021 | |
| Pfizer INC. | $43.52 | 2021-2023 | |
| Lilly USA, LLC | $41.26 | 2024-2025 | Omvoh |
| Merck Sharp & Dohme LLC | $35.96 | 2023-2024 | Dificid |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $34.95 | 2021-2024 | |
| Pharmacosmos Therapeutics INC. | $33.65 | 2025 | Monoferric |
| Ipsen Biopharmaceuticals, INC | $32.48 | 2023-2024 | Iqirvo, Bylvay |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.20 | 2023 | Cyltezo |
| Nestle Healthcare Nutrition INC. | $31.14 | 2023 | |
| Ucb, INC. | $30.67 | 2021-2022 | |
| Abbvie INC. | $28.04 | 2023-2024 | |
| Celltrion USA INC. | $25.78 | 2024 | Vegzelma |
| Recordati_rare_diseases_inc. | $25.28 | 2025 | Panhematin |
| Tersera Therapeutics LLC | $22.84 | 2024 | Xermelo |
| Enterra Medical, INC. | $21.78 | 2022 | |
| Axonics, INC. | $19.17 | 2021 | |
| Mylan Institutional INC. | $16.20 | 2023 | Hulio |
| Amgen INC. | $15.41 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $13.74 | 2023 | Dupixent |
| Aimmune Therapeutics, INC. | $13.20 | 2024 | |
| Novo Nordisk INC | $11.85 | 2022 | |
| Phathom Pharmaceuticals, INC. | $10.07 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Keech listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.